Image source: The Motley Fool.
DATE
Thursday, Aug. 14, 2025 at 10 a.m. ET
CALL PARTICIPANTS
Chief Executive Officer — Ric Phillips
Chief Financial Officer — Jana Croom
Need a quote from a Motley Fool analyst? Email [email protected]
RISKS
Automotive Sales— The loss of the electronic braking program in Reynosa will negatively impact annual sales by $60 million in fiscal 2026, as the program is being transferred to another source under a commercial agreement with the OEM.
Annual Revenue Outlook— Guidance projects net sales to decrease 2%-9% in fiscal 2026, reflecting the absence of the large consigned inventory sale and the divested braking program.
Gross Margin Pressure— Gross margin rate declined by 50 basis points to 8% in Q4 fiscal 2025 due to lower absorption from reduced sales, though management noted sequential improvement.
Tax Rate Elevation— The effective tax rate (GAAP) was 48.3% in Q4 fiscal 2025 and is guided to the low-30% range for fiscal 2026, elevated by factors such as GILTI income and withholding taxes.
TAKEAWAYS
Net Sales-- $380.5 million, a 12% year-over-year decrease and an 8% decline excluding the automation test and measurement (AT and M) business divestiture, for Q4 fiscal 2025.
Sequential Revenue-- Companywide net sales increased 2% quarter over quarter in Q4 fiscal 2025; the recurring revenue improvement was more pronounced after adjusting for the prior quarter’s $24 million non-recurring medical inventory sale.
Medical Segment Performance-- Generated $107 million in Q4 fiscal 2025, up 5% year over year and representing 28% of total sales, with renewed growth from its largest medical customer as Kimball became the sole supplier for respiratory care assemblies.
Automotive Segment-- Net sales were $184 million for Q4 fiscal 2025, a 13% year-over-year decline, largely due to the end of the Reynosa braking program. This was partially offset by ramp-up in Romania, though demand for EV steering systems remained soft.
Industrial Segment-- Net sales reached $90 million in Q4 fiscal 2025, 12% lower year over year excluding AT and M, with broad-based declines in North America and Europe offsetting signs of stability in climate control; Asian revenues were flat.
Gross Margin Rate-- 8%, down from 8.5% a year ago, reflecting lower absorption on reduced sales but showing sequential improvement in Q4 fiscal 2025.
Adjusted SG&A Expenses-- $10.8 million, representing 2.8% of sales, down from 3.2% a year earlier, driven by cost reduction initiatives and portfolio alignment for Q4 fiscal 2025 (adjusted, non-GAAP).
Adjusted Operating Income-- Adjusted operating income for Q4 fiscal 2025 was $19.6 million or 5.2% of sales, compared to $22.7 million or 5.3% in Q4 fiscal 2024. This marked the third consecutive quarter of operating income growth, both in dollars and as a percentage of sales.
Adjusted Net Income-- Adjusted net income in Q4 fiscal 2025 was $8.4 million, or $0.34 per diluted share, versus $9.7 million, or $0.38 per diluted share, in Q4 fiscal 2024.
Cash Flow and Working Capital-- Operating cash flow was $78.1 million for Q4 fiscal 2025. Cash conversion days improved to 85 from 100 a year ago and 99 last quarter, with further reductions targeted.
Inventory-- Inventory ended Q4 fiscal 2025 at $273.5 million, down $23.1 million sequentially and $64.6 million (19%) year over year.
Debt Reduction-- Borrowings were $147.5 million as of Q4 fiscal 2025, down $31.3 million from the prior quarter and 50% lower than at the start of the fiscal year.
Liquidity-- Short-term liquidity stood at $380.5 million, including cash and unused credit facilities as of Q4 fiscal 2025.
Share Repurchases-- $3 million was used to buy back 162,000 shares in Q4 fiscal 2025; $16.3 million remains authorized for repurchases.
Fiscal 2026 Guidance-- Projects net sales of $1.35-$1.45 billion (down 2%-9%) for fiscal 2026, an adjusted operating income margin of 4%-4.25%, and capital expenditures between $50 million and $60 million, weighted toward the new Indianapolis facility.
Medical CMO Capacity Expansion-- The Indianapolis facility opening in November spans 300,000 square feet, with 'well in excess of half a billion' dollars in potential revenue capacity, as stated by management; no GAAP or non-GAAP designation is provided for this figure.
SG&A Margin Guidance-- Adjusted SG&A is expected to run at approximately 3.5% of revenue.
Tax Rate Outlook-- The fiscal 2026 effective tax rate (GAAP) is projected in the low-30% range, down from 35% in fiscal 2025 and 48.3% in Q4 fiscal 2025.
SUMMARY
Management emphasized progress in shifting its portfolio toward medical contract manufacturing, supported by a record number of new business wins and a significant Indianapolis facility investment. Margin expansion potential was attributed to higher-value and automated medical assembly, with stated intent to pursue both organic and inorganic opportunities in the medical CMO space. Leaders described further opportunities to improve working capital efficiency, targeting a reduction in cash conversion days from the current 85 in Q4 fiscal 2025 toward the mid-70s through new initiatives to be rolled out in fiscal 2026. Company statements highlighted the approach of communicating a pass-through expectation for tariffs to customers. An expanded focus on business development in medical, including new hires and consolidated leadership, was noted.
Ric Phillips said, “we expect to continue to generate positive cash flow, and we will deploy that capital toward growing the CMO.”
Jana Croom indicated the new sole-source medical contract is without “any changes to the contract terms.” implying stable margin profile for the restarted business.
Facility automation and scale are expected to generate accretive margins in medical, with Ric Phillips confirming, “There will absolutely be a lot of automation there. We expect that that CMO segment will be accretive to our margins over time,”
Management characterized industry inventory practices as returning to normal, offering additional opportunity to “drive higher levels of cash from our EMS operations while continuing to reduce CCD”
Intent to build “it's about building a scalable platform that supports the work we already do well, creates opportunities for vertical integration, and positions us to take on more of the complex programs that align with our strengths.” was cited as a foundation for future growth.
INDUSTRY GLOSSARY
AT and M (Automation Test and Measurement): Business unit previously part of Kimball Electronics, Inc. portfolio, now divested and excluded from comparable year-over-year figures.
CMO (Contract Manufacturing Organization): An entity that manufactures products for other companies, emphasizing medical device assembly and related regulated activities.
CCD (Cash Conversion Days): The average number of days it takes to convert investment in inventory and other resources into cash flows from sales.
PDSOH (Projected Days Supply On Hand): Inventory management metric estimating the average number of days that available supply will last given projected demand.
HLA (Higher Level Assembly): Assembly of subcomponents into complex, finished devices, typically offering higher margins than basic components manufacturing.
Full Conference Call Transcript
Ric will start the call with a few opening comments. Jana will review the financial results for the quarter and guidance for fiscal 2026. Ric will complete our prepared remarks before taking your questions. I'll now turn the call over to Ric.
Ric Phillips: Thanks, Andy. And good morning, everyone. I'm encouraged by the results for the fourth quarter and the solid finish to the fiscal year. Q4 came in better than expectations as sales increased sequentially, margins continued to improve, and working capital management drove our sixth consecutive quarter of positive cash flow, which was used to pay down debt. Our balance sheet is now in a position of competitive strength, with ample liquidity to weather an unpredictable environment while providing dry powder for opportunistic investments. In total, fiscal 2025 was a year of controlling what we could control. I am proud of our team as we made significant progress positioning the company for a return to profitable growth with noteworthy accomplishments.
Including a record number of wins for future business, a meaningful increase in the number of green customer scorecards, quality ratings at a fifteen-year high, adjusting the cost structure and aligning the portfolio to demand trends, and intensifying our focus as a medical CMO. The new 300,000 square foot medical facility in Indianapolis we announced last quarter is an important milestone in this strategy. It provides the space needed to expand our production capabilities beyond traditional printed electronics and circuit board assemblies, encompassing cold chain management, complete device assembly, and precision molded plastics. Our current manufacturing includes medical disposables, single-use surgical instruments, and selected drug delivery devices such as auto-injectors.
Additionally, we're looking to expand applications in areas such as cardiology, orthopedics, minimally invasive surgery, and surgical instruments and packaging. The medical market presents a compelling opportunity to diversify revenue and leverage our core strengths as a trusted partner in a complex and regulated industry. We expect fiscal 2026 to be another step forward in this journey. We anticipate positive top-line growth for the company overall in FY 2027. As we return to growth, better capacity utilization will result in higher margins. Turning now to the fourth quarter. Net sales for the company were $381 million, an 8% decline compared to Q4 last year, when excluding the automation test and measurement business that was divested.
For the second consecutive quarter, our medical business grew year over year, while the other two verticals we serve reported declines. Sequentially, however, the top line increased 2% compared to Q3. Remember, the third quarter included a $24 million non-recurring consigned inventory sale in the medical vertical. So the sequential sales for recurring business are even more encouraging beneath the surface. Sales in Medical were $107 million, up 5% compared to the same period last year and 28% of total company sales. The increase in Q4 was driven by a step-up in sales with our largest medical customer. A welcomed reprieve after a long period of decline during the FDA recall.
We expect the growth with this customer to continue, as we were selected as the sole supplier for their respiratory care final assembly and higher-level assemblies business, with most of the production occurring in our facility in Thailand. Similar opportunities are possible as the population ages, access and affordability to healthcare increases, medical devices get smaller in size and require higher levels of precision and accuracy, and connected drug delivery systems become more common as consumer adoption increases. In general, HLAs and finished medical devices are great business for us as the cost of sales is lower, and the revenue potential is higher than what is customary with contract manufacturing in EMS. And this business increases our stickiness with customers.
Next is automotive, with net sales of $184 million, a 13% decrease compared to the fourth quarter of last year and 48% of the total company. The decline in Q4 was driven by the electronic braking program that, as previously announced, is no longer being produced in Reynosa. As a result of a commercial agreement by the OEM to transfer to another source. This impact was partially offset by the ramp-up of a similar but separate braking program in Romania. In addition, we continue to carefully monitor the demand for electronic steering systems for EVs, which were lower in the quarter.
Finally, industrial, with net sales of $90 million, down 12% year over year when excluding AT and M, and representing 24% of total company sales. We see early signs of stability with climate control systems, but this was offset by broad-based declines in other industrial segments in North America and Europe. Asia was approximately flat in Q4. I'll now ask Jana to provide more detail on the financial results for Q4 and our guidance for fiscal 2026. Jana?
Jana Croom: Thank you. And good morning, everyone. As Ric detailed, net sales in the fourth quarter were $380.5 million, a 12% decrease year over year, down 8% when excluding AT and M. Foreign exchange had a 1% favorable impact on consolidated sales in Q4. The gross margin rate in Q4 was 8%, a 50 basis point decrease compared to 8.5% in the same period of fiscal 2024, with lower absorption and outcome from reduced year-over-year sales driving the decline in rate. However, representing significant sequential improvement over the course of the fiscal year.
Adjusted selling and administrative expenses in the fourth quarter were $10.8 million, a $3.2 million or 23% reduction compared to the $14 million we reported in Q4 last year. The decrease occurred from our cost reduction efforts, reduced bonus expense, and not having AT and M in our portfolio this year versus a full quarter of expense in fiscal 2024. When measured as a percentage of sales, adjusted selling and administrative expenses were 2.8%, a 40 basis point improvement compared to 3.2% in 2024. This is consistent with our commitment to control what we can control, with all four quarters in the year at an adjusted SG&A rate of 3% of sales or lower.
Adjusted operating income for the fourth quarter was $19.6 million or 5.2% of net sales, which compares to last year's adjusted results of $22.7 million or 5.3% of net sales. The third consecutive quarter of growth in absolute dollars and as a percentage of net sales. Other income and expense was an expense of $3.8 million compared to $6.1 million of expense last year, with interest expense, which was down nearly 50% year over year, responsible for the change. The effective tax rate in the fourth quarter was 48.3% compared to 44% in 2024.
As you may recall, last year's rate was skewed higher by the impacts of a domestic valuation allowance and the impairment and restructuring charges associated with AT and M. We ended the year with an effective tax rate of 35%, driven by the inclusion of GILTI income, which is subject to U.S. taxation despite being earned by our foreign subsidiaries, and withholding tax related to cash repatriation from our foreign subsidiaries, which is offset by lower interest expense on our borrowings. In fiscal 2026, we expect a tax rate in the low 30%.
Adjusted net income in Q4 2025 was $8.4 million or $0.34 per diluted share compared to adjusted net income in Q4 last year of $9.7 million or $0.38 per diluted share. Turning now to the balance sheet. Cash and cash equivalents at June 30, 2025, were $88.8 million. Cash generated by operating activities in the quarter was $78.1 million, our sixth consecutive quarter of positive cash flow. Cash conversion days were 85 days compared to 100 days in Q4 fiscal 2024 and 99 days last quarter. This represents our lowest CCD in three years, with the decrease this quarter compared to Q3 driven by all components of the calculation, with PDSOH showing the strongest improvement.
We see additional opportunity to drive higher levels of cash from our EMS operations while continuing to reduce CCD with new working capital initiatives that will be rolled out in FY 2026. Inventory ended the quarter at $273.5 million, a $23.1 million reduction compared to Q3 and $64.6 million or 19% lower than a year ago. Capital expenditures in the fourth quarter were $9.6 million. For the full year, CapEx was $33.7 million, primarily to support new product introductions and maintenance needs. Borrowings at June 30, 2025, were $147.5 million, a $31.3 million reduction from the third quarter and down $147.3 million or 50% from the beginning of the fiscal year.
Short-term liquidity available, represented as cash and cash equivalents plus the unused portion of our credit facilities, totaled $380.5 million at the end of the fourth quarter. We invested $3 million in Q4 to repurchase 162,000 shares. Since October 2015, under our Board-authorized share repurchase program, a total of $103.7 million has been returned to our shareholders by purchasing 6.6 million shares of common stock. We have $16.3 million remaining on the share repurchase program. As Ric mentioned, fiscal 2025 was a year of controlling what we could control, and I am proud of our team's resilience and discipline. We made substantial progress adjusting our cost structure to demand trends throughout the year.
We improved our balance sheet with working capital initiatives and aligned the portfolio for future growth expectations. We ended fiscal 2025 with net sales totaling $1.487 billion, the third highest annual revenue total in the sixty-year history of the company. Adjusted operating income of $61.3 million or 4% of net sales, inventory down nearly 20% year over year, cash generated by operating activities of $183.9 million, a record result for annual cash flow. CCD at our lowest level in three years, and debt paid down 50% in the fiscal year and at its lowest level in three years. And $12 million invested to repurchase 653,000 shares of common stock.
Fiscal 2026 will be a year of transition with net sales in the range of $1.35 to $1.45 billion, a 2% to 9% decrease compared to fiscal 2025, adjusted operating income in the range of 4% to 4.25% of net sales compared to 4.1% of net sales in fiscal 2025, and capital expenditures in the range of $50 million to $60 million. To put our sales guidance in perspective, two important events occurred in fiscal 2025 that have been normalized when planning for fiscal 2026. The loss of the braking program in Reynosa will have a $60 million unfavorable impact in the year. In addition, we do not expect another large consigned inventory sale similar to Q3 to occur again.
Without these two items, our top-line guide is approximately flat year over year. We expect modest growth in our Medical and Industrial businesses, but it will be offset by a decline in automotive. Margins are estimated to be in line with FY 2025 as we repurpose some of the benefit of the Tampa closure to focus on growing the CMO and our core EMS business. It's important to note that when top-line growth returns, enhancements to our cost structure should support margin improvement. Capital expenditures will be heavily weighted to our new facility in Indianapolis, approximately $30 million, with the balance supporting growth, automation, and maintenance. I'll now turn the call back over to Ric.
Ric Phillips: Thanks, Jana. Before we open the lines for questions, I'd like to share a few thoughts in closing. Our company has always focused on high complexity, high reliability programs, whether it's braking and steering systems in vehicles, motor controls for HVAC systems, or diagnostic and therapeutic equipment in the medical field. The emphasis on quality and reliability is deeply embedded in how we operate across all verticals. Internally, we reference a five nines reliability standard, 99.999%, as a reflection of the performance and consistency we strive for. The medical CMO aligns well with this objective and our expertise in a highly regulated, highly engineered, complex manufacturing environment.
We're approaching our medical CMO strategy with additional steps to position the company for long-term profitable growth. As Jana mentioned, we expect to continue to generate positive cash flow, and we will deploy that capital toward growing the CMO. As we evaluate the medical CMO space, we see opportunity for higher EBITDA margins. Our strategy is to pursue growth with blue-chip customers with long product life cycles and a high degree of visibility. It's not just about adding capabilities; it's about building a scalable platform that supports the work we already do well, creates opportunities for vertical integration, and positions us to take on more of the complex programs that align with our strengths.
Drug delivery has been a key area of focus for us. Our capabilities are well established, and with the new Indianapolis facility, we believe we're well positioned to meet current and future customer needs, but we're also committed to pursuing inorganic options to augment this space where it makes strategic sense. Throughout this journey, we will stay true to our guiding principles and continue to be collaborative and team-oriented, set high long-term aspirations, not unrealistic goals, but attainable targets that require stretching, communicate openly and proactively, and remain accountable to our company, to our customers, to each other, and to our shareholders.
In closing, I'd like to thank the entire Kimball Electronics, Inc. team for their hard work, focus, and dedication as we build tomorrow together. I've never been more excited about the future of the company. Thank you for your support. Daryl, we would now like to open the lines for questions.
Operator: Thank you. You may remove yourself from the queue by pressing star 2 on your dial pad. We ask that if you are using a speakerphone, you pick up your handset before asking your question. Our first questions come from the line of Mike Crawford with B. Riley Securities. Please proceed with your questions.
Mike Crawford: Thank you. Can you remind us the timing of when the new facility in Indianapolis will be ready and the potential revenue capacity of that building?
Ric Phillips: Yes, Mike. Thanks for joining us. So we are planning to grand opening that facility in November. We're obviously working on it as it was a completely empty new building. So we're working on that. At that point, we will start to get equipment in there and get ready to produce. That facility is at 300,000 square feet and has a lot of capacity for growth. In addition to that, the way that space is configured, we could expand further from there as needed. But we could handle hundreds of millions of dollars of business in that facility, depending on the size of programs that ramp up.
Jana Croom: Well in excess of half a billion.
Mike Crawford: Okay. Great. And I'm pleased to hear your capital allocation focus on the medical CMO. What about some other directions you've been considering the past year, like industrial, Jason?
Ric Phillips: Yes. So we continue to, Mike, try to take a really sharp strategic lens to where we're focused. We have been in some interesting discussions in industrial, to your point, which would get us beyond areas that we're currently in. We don't have anything to announce on that front at this point. In automotive, we continue, as you know, to feel that the steering and braking that we've been focused on is a great fit for us and gives us great potential moving forward. So we do think it's a combination, obviously a big ramp-up in the medical CMO, but we see opportunities across all of our verticals.
Mike Crawford: Okay. Thank you. And then just one last one for me. It's nice to hear you're sole source for Philips in Thailand, and I guess that you don't really have that many tariff issues with them given their problems in the US. But, what about tariffs in general for your global footprint? Thank you.
Ric Phillips: Yes. Just a couple of comments on that. I mean, one reminder is that for the majority of our business, we are not typically the importer of record, which provides us a little bit of protection. We also have a mindset and approach with our customers that the tariffs are a pass-through. So if they hit us, they hit others. The other thing that we've done is just take some no-regrets moves given how uncertain the tariff environment is. So we talk to our customers and are clear on the pass-through approach that we expect.
We talk to customers proactively about, as you well know, we have a global network, and if you want to leverage it in a different way, based on your strategy and how tariffs are affecting you, we're happy to talk about leveraging all of our facilities. And we also work to qualify alternative sources of supply in different countries just to provide flexibility depending on which directions those go. So that's been our approach. And like everyone else, wake up in the morning and see what changed. We're trying to be flexible and take that approach.
Mike Crawford: Great. Thank you.
Operator: Thank you. Our next questions come from the line of Derek Soderberg with Cantor Fitzgerald. Please proceed with your questions.
Derek Soderberg: Yes. Hey, everyone. Congrats on the results. Thanks for taking the questions. I want to start with the large medical customer. You're going to be the sole supplier with final assembly, higher-level assembly, with that customer. Can you remind us what you were doing for the respiratory program the last time? Was it a similar type of arrangement? Was wondering if you can comment on sort of the margin profile change of that program.
Jana Croom: So there's not really a margin profile change from what we were producing with them before. We're just starting to produce for them again, which is a really good sign. It's been a great customer. We were doing higher-level full final assembly for them prior. And there have not really been material changes, really any changes to the contract terms. We're just starting up again, which feels really, really great.
Derek Soderberg: Got it. And, Jana, did you say that program was coming out of Thailand, your Thailand facility?
Jana Croom: Yes, it's coming out of our Thailand facility.
Derek Soderberg: Got it. Got it. Okay. So that's helpful. Actually, let me restate that because what I just said was not entirely correct. We had started off the relationship doing printed circuit board assemblies. We had moved into doing some full and final assembly for them, but they had their own footprint in the US. We will be doing full and final assembly for all of their manufacturing now. They won't be doing any of it. It will all be supported by us. And there's not a second supplier, it's Kimball solely.
Derek Soderberg: Got it. Got it. That's great to hear. And then, Jana, while I have you, debt levels here are pretty low. Actually wanted to discuss the cash conversion days. Improving quite a bit here. Is there sort of a structural new low for you guys as a company? It sounds like there's some room to improve that. What sort of changing are these sort of initiatives you're taking as a company that's improving this? Is the industry kind of changing? What, can you talk about some of those initiatives and I guess how much room you have to continue to improve that number? Thanks.
Jana Croom: Yes, that's a great question. I don't know so much that the industry is changing as much as things are a pendulum, right? And so you had just-in-time inventory and then COVID hit, and then everybody said, we want you to carry a ton of inventory, and we said, well, that's fine, but you've got to give us carrying costs on that inventory. And what you're seeing is more of a return to normal, right? So sixty-five days is too tight, but one hundred days is too wide. We're sitting at eighty-five days now with a goal to get down more towards seventy-five-ish days. And there are a variety of things that you can do.
You can offer AR factoring programs. You can offer supplier financing programs. It's really about controlling AR and AP days as you think about what that means for your DSO. PDSOH is much more a function of working with the customer on inventory turns. How much safety stock do we really need to have, getting better controls over longer line of sight around production and volume levels fifteen, eighteen, twenty-four months out, which has been something that I do believe the industry in total has been challenged with. And so just really getting better about that discipline and partnership with your entire supply chain.
Derek Soderberg: Got it. That's super helpful. Jana. Thanks, everyone.
Operator: Thank you. Our next questions come from the line of Anja Soderstrom with Sidoti and Company. Please proceed with your questions.
Anja Soderstrom: Hi. Congratulations on a nice progress here and thank you for taking my questions. So in terms of the margin improvement, is that mainly going to be driven by the operating margin then?
Jana Croom: Well, it's so gross margin you're going to see improvement, and that's the result of a lot of the restructuring that we've done, capacity utilization efforts, shutdown in Tampa. We've got controls on the SG&A side and a real discipline there too. There's going to be some investment that we make in order to grow, and I alluded to that on the Q3 call. Investments around IT innovation that we need to make, investments in business development that are just going to help shore us up for future growth. But as we have more revenue, similar to the question we got about HLA and final finished assembly, more revenue translates into better capacity utilization, translates into higher margin. Right?
And so that is what you should see once we sort of get past FY '26. Is that really opening up in a more material way as we begin to grow again?
Anja Soderstrom: Okay. And just still expect the adjusted SG&A to be around 3% of revenue?
Jana Croom: 3.5%. Okay. This is our history. Yeah. Three and a half.
Anja Soderstrom: So it won't sustainably stay at three, I think I alluded to that on the 3Q call. Okay. Thank you. And then also in terms of you shifting a little bit more focus onto the medical segment, what kind of changes are you making to your sort of sales organization and go-to-market strategy?
Ric Phillips: Yeah. No. It's a great question, Anja, and thanks for joining. Yes, so we're making hires in business development as one straightforward path. As you know, we brought our medical businesses together a year or so ago, and in doing so really leverages our strong and experienced leaders across the entirety now of that medical vertical. And we've also undertaken a pretty comprehensive marketing plan, particularly to support the CMO efforts as we now have capability to do things at a scale and at a technology level that we weren't able to before. So, yes, we are making big investments, as you can imagine, with that new facility.
On the sales side to put effort around that to drive that business over time.
Anja Soderstrom: And would you go more heavily into that? Has that changed your sort of competitive landscape, the guys you compete against, or is it still the same?
Ric Phillips: It could have some changes there. What is a great differentiator for us relative to traditional competitors is we have the FDA experience and we have the capability to actually handle the drug. So that, from what our customers tell us, that's a big advantage that allows us to be more sticky with them, allows us to play a bigger role in what they're doing as well.
Anja Soderstrom: Okay. Thank you. And then I'm just curious with the Indiana, the new facility there. Will there be a lot of automation there, and how does that sort of affect the margins?
Ric Phillips: There will absolutely be a lot of automation there. We expect that CMO segment will be accretive to our margins over time, just because of the characteristics of the space. So there'll certainly be significant investments in equipment and automation. But we still think that space sets us up for margin accretion.
Anja Soderstrom: Okay. Thank you. That was all for me.
Operator: Thank you. Our next questions come from the line of Jason Schwei with Lake Street Capital Markets. Please proceed with your questions.
Jason Schwei: Hey, thanks for taking my questions. Looking at that medical segment, obviously, the customer you called out should be a driver here. But are there other pockets of strength that you're expecting in that segment for this year?
Ric Phillips: Yes. We've actually introduced a number of customers, some we've talked about in the past and some we haven't. But we are definitely seeing incremental growth over time in medical beyond that customer. In fact, most of the new customers that we've introduced over the last two years have been in that medical segment. So we do see opportunity to expand. We think our capabilities fit well. The shift that we've had over time really demonstrated capability there. The shift to full assembly gives us more opportunities and
Jason Schwei: Okay. That's really helpful. And maybe not even looking at fiscal 2026, but longer term, when you think about sort of driving growth in this business, how are you thinking about prioritizing sort of new customers versus expanding the number of programs that exist with existing customers? Or really just kind of hoping that the demand profile of the programs you've already won just improves?
Ric Phillips: Great question. I'd say all of the above. I mean, the quickest return to growth is the programs that already won a couple of years ago where the demand has been softer than originally projected. Comes back. We can't control that, but it certainly would be a short-term driver. But beyond that, we are aggressively hunting new business. We are working very closely. And I feel like our customer relationships across the board are as good as they've ever been. With existing customers and new programs coming to us. So we think it'll be a combination of all those things. The area where you'll probably see the biggest new customer introduction will be the medical space.
Jason Schwei: Okay. That's really helpful. I'll jump back into queue. Thanks, guys.
Operator: Thank you. We have reached the end of our question and answer session. And with that, ladies and gentlemen, this does now conclude today's conference call. The telephone replay will be available approximately three hours after the conclusion of this event. You can access the replay by dialing (877) 660-6853 or (201) 612-7415. The replay will be available until August 28, 2025, using access ID 13755051. Thanks again for your participation. You may disconnect at this time. Enjoy the rest of your day.